推动仿制药品发展须紧贴民生需求

Core Viewpoint - The fourth batch of encouraged generic drug catalog includes 21 varieties and 47 specifications, focusing on patient treatment needs and addressing weak R&D areas in domestic companies [1][2]. Group 1: Drug Catalog and Patient Needs - The new catalog includes drugs for oncology, nervous system, assisted reproduction, and radioactive diagnosis, prioritizing products with new targets and mechanisms [1]. - The inclusion of low-adverse reaction assisted reproductive drugs aligns with the promotion of fertility policies, providing significant support for families wishing to have children [2]. - The catalog also features domestically practiced products, such as deflazacort for treating rare diseases, which can alleviate urgent patient needs [2]. Group 2: Policy Implementation and Industry Development - Effective accessibility to generic drugs relies on the implementation of supportive policies, with the National Health Commission establishing a communication mechanism to promote R&D, registration, production, and reimbursement [3]. - The selection of drugs in the fourth batch reflects a comprehensive consideration of patient needs, aiming to provide high-quality and effective options for both common and rare diseases [3]. - This approach not only demonstrates a commitment to patient welfare but also indicates a direction for the sustainable development of the generic drug industry, addressing the challenges of medication accessibility [3].